UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000636
Receipt number R000000771
Scientific Title The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.
Date of disclosure of the study information 2008/08/30
Last modified on 2008/11/18 20:12:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

Acronym

The clinical effects of additional repeated intraperitoneal Paclitaxel for advanced gastric cancer.

Scientific Title

The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

Scientific Title:Acronym

The clinical effects of additional repeated intraperitoneal Paclitaxel for advanced gastric cancer.

Region

Japan


Condition

Condition

Far advanced or recurrent gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the efficacy and safety of the repeated intraperitoneal Paclitaxel for non-resectable gastric cancer, especially that with peritoneal dissemination.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

side effects
1-year survival

Key secondary outcomes

plasma level of taxol
response rate
Duration of overall Response
Duration of complete Response
Duration of Stable DiseaseTime To Progression


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

1.Oral TS-1 80mg/m2 every day
2.Intravenous Paclitaxel 50mg/m2 every week
3.intraperitoneal Paclitaxel every week
2 week administration and 1 week off
x3 cycles

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Non-resectable gastric cancer with peritoneal dissemination, or positive peritoneal cytology.

Key exclusion criteria

Other hematogeneous metastasis
multiple cancers
other cases who are decided to be inappropriate for the clinical trial by doctors.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Joji Kitayama

Organization

The University of Tokyo

Division name

Department of Surgical Oncology

Zip code


Address

Hongo 7-3-1, Bunkyo-ku, Tokyo

TEL

03-3815-5411.33246

Email



Public contact

Name of contact person

1st name
Middle name
Last name Joji Kitayama

Organization

The University of Tokyo

Division name

Department of Surgical Oncology

Zip code


Address

Hongo 7-3-1, Bunkyo-ku, Tokyo

TEL

03-3815-5411

Homepage URL

http://all-1su.umin.jp/ip_pacli.html

Email

kitayama-1SU@h-u-tokyo.ac.jp


Sponsor or person

Institute

Department of Surgical Oncology
The University of Tokyo

Institute

Department

Personal name



Funding Source

Organization

Grants-in-Aid for Scientific Research Japan society of the promotion of science

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 08 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2006 Year 07 Month 27 Day

Date of IRB


Anticipated trial start date

2006 Year 08 Month 01 Day

Last follow-up date

2008 Year 07 Month 01 Day

Date of closure to data entry

2008 Year 07 Month 01 Day

Date trial data considered complete

2010 Year 07 Month 01 Day

Date analysis concluded

2010 Year 07 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 03 Month 12 Day

Last modified on

2008 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000771


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name